Table of Contents Author Guidelines Submit a Manuscript
Journal of Nucleic Acids
Volume 2012 (2012), Article ID 269570, 9 pages
Review Article

Splicing Programs and Cancer

Sophie Germann,1,2,3,4 Lise Gratadou,1,2,3,4 Martin Dutertre,1,2,3,4 and Didier Auboeuf1,2,3,4

1Université de Lyon, 28 rue Laënnec, 69008 Lyon, France
2Inserm U1052, 28 rue Laënnec, 69008 Lyon, France
3CNRS UMR5286, 28 rue Laënnec, 69008 Lyon, France
4Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, 28 Rue Laënnec, 69008 Lyon, France

Received 26 July 2011; Accepted 23 August 2011

Academic Editor: Juan Valcarcel

Copyright © 2012 Sophie Germann et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Numerous studies report splicing alterations in a multitude of cancers by using gene-by-gene analysis. However, understanding of the role of alternative splicing in cancer is now reaching a new level, thanks to the use of novel technologies allowing the analysis of splicing at a large-scale level. Genome-wide analyses of alternative splicing indicate that splicing alterations can affect the products of gene networks involved in key cellular programs. In addition, many splicing variants identified as being misregulated in cancer are expressed in normal tissues. These observations suggest that splicing programs contribute to specific cellular programs that are altered during cancer initiation and progression. Supporting this model, recent studies have identified splicing factors controlling cancer-associated splicing programs. The characterization of splicing programs and their regulation by splicing factors will allow a better understanding of the genetic mechanisms involved in cancer initiation and progression and the development of new therapeutic targets.